Human Longevity stock

Human Longevity Stock

HealthTech

Looking to sell Human Longevity stock or options?

Contact us
Founded: 2013Funding to Date: $69M
Visit website

Human Longevity is the creator of a biotechnology platform that merges genomic and phenotypic data to expedite the comprehension of human health. The platform of this company focuses on age-related decrease in innate stem cell functionality and targets diseases such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By incorporating DNA sequencing and expert scrutiny with machine learning, Human Longevity provides individuals the ability to influence their health and transition the medical practice from reactive to proactive methodologies.

Investors Include:

Robert Duggan, Surender Punia, Thierry Marbach, Bryan Johnson, BB Retail Capital, Reid Robison, Adam Hudson, Steven Kaplan, CONNECT (Accelerator), Roger Kaser, Singularity (Consulting Services (B2B)), StartUp Health, Daniel Curran, Peter Diamandis, San Diego Regional Economic Development Corporation, Ryan Chorazy, Shin Ryoku Trust, Synergy Growth, Rolf Mathies, Ping Wu, Oceanpine Healthcare Fund, Panacea Venture, Illumina, NKM Capital, PTK Capital.

Collective Representative

Looking to sell Human Longevity Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you

Loading